These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 24860788)
1. Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Hu Z; Slayton WB Front Oncol; 2014; 4():112. PubMed ID: 24860788 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902 [TBL] [Abstract][Full Text] [Related]
3. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079 [TBL] [Abstract][Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
5. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. Wu N; Kurosu T; Oshikawa G; Nagao T; Miura O Int J Oncol; 2013 Feb; 42(2):419-28. PubMed ID: 23233201 [TBL] [Abstract][Full Text] [Related]
6. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006 [TBL] [Abstract][Full Text] [Related]
7. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524 [TBL] [Abstract][Full Text] [Related]
8. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hunger SP Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058 [TBL] [Abstract][Full Text] [Related]
11. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368 [TBL] [Abstract][Full Text] [Related]
12. Involvement of BCR::ABL1 in laminin adhesion of Philadelphia chromosome-positive acute lymphoblastic leukemia through upregulation of integrin α6. Takahashi K; Nguyen TTT; Watanabe A; Sato H; Saito K; Tamai M; Harama D; Kasai S; Akahane K; Goi K; Kagami K; Abe M; Komatsu C; Maeda Y; Sugita K; Inukai T Cancer Rep (Hoboken); 2024 Apr; 7(4):e2034. PubMed ID: 38577721 [TBL] [Abstract][Full Text] [Related]
13. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. Irwin ME; Nelson LD; Santiago-O'Farrill JM; Knouse PD; Miller CP; Palla SL; Siwak DR; Mills GB; Estrov Z; Li S; Kornblau SM; Hughes DP; Chandra J PLoS One; 2013; 8(8):e70608. PubMed ID: 23936456 [TBL] [Abstract][Full Text] [Related]
14. [Regulatory effect of integrin alpha5 and beta1 on proliferation inhibition of K562 cells induced by interferon alpha-2b]. Niu ZY; Pan L; Zhang XJ; Liu YJ Ai Zheng; 2006 Mar; 25(3):297-302. PubMed ID: 16536982 [TBL] [Abstract][Full Text] [Related]
15. Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells. Zhang C; Zhang X; Yang SJ; Chen XH Oncol Lett; 2017 Apr; 13(4):2059-2070. PubMed ID: 28454362 [TBL] [Abstract][Full Text] [Related]
16. BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia. Kuroda I; Inukai T; Zhang X; Kikuchi J; Furukawa Y; Nemoto A; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Yagita H; Tauchi T; Maeda Y; Sugita K Oncogene; 2013 Mar; 32(13):1670-81. PubMed ID: 22665066 [TBL] [Abstract][Full Text] [Related]